- Topic
18k Popularity
11k Popularity
42k Popularity
17k Popularity
40k Popularity
18k Popularity
6k Popularity
3k Popularity
95k Popularity
28k Popularity
- Pin
- 🚨 Gate Alpha Ambassador Recruitment is Now Open!
📣 We’re looking for passionate Web3 creators and community promoters
🚀 Join us as a Gate Alpha Ambassador to help build our brand and promote high-potential early-stage on-chain assets
🎁 Earn up to 100U per task
💰 Top contributors can earn up to 1000U per month
🛠 Flexible collaboration with full support
Apply now 👉 https://www.gate.com/questionnaire/6888
- 🔥 Gate Square #Gate Alpha Third Points Carnival# Trading Sharing Event - 5 Days Left!
Share Alpha trading screenshots with #Gate Alpha Trading Share# to split $100!
🎁 10 lucky users * 10 USDT each
📅 July 4, 4:00 – July 20, 16:00 UTC+8
Gate Alpha 3rd Points Carnival Issue 10 is in full swing!
Trade and post for double the chances to win!
Learn more: https://www.gate.com/campaigns/1522alpha?pid=KOL&ch=5J261cdf
- 🎉 [Gate 30 Million Milestone] Share Your Gate Moment & Win Exclusive Gifts!
Gate has surpassed 30M users worldwide — not just a number, but a journey we've built together.
Remember the thrill of opening your first account, or the Gate merch that’s been part of your daily life?
📸 Join the #MyGateMoment# campaign!
Share your story on Gate Square, and embrace the next 30 million together!
✅ How to Participate:
1️⃣ Post a photo or video with Gate elements
2️⃣ Add #MyGateMoment# and share your story, wishes, or thoughts
3️⃣ Share your post on Twitter (X) — top 10 views will get extra rewards!
👉
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.